Transactions in connection with share buy-back program
COPENHAGEN, Denmark; March 06, 2023 –Genmab A/S (Nasdaq: GMAB). On February 22, 2023, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.
The share buy-back program is expected to be completed no later than March 31, 2023 and comprises up to 220,000 shares.
The following transactions were executed under the program from February 27, 2023, to March 03, 2023:
|No. of shares||Average price (DKK)||Total value (DKK)|
|Accumulated through last announcement||22,000||58,232,120|
|February 27, 2023||10,000||2,687.64||26,876,400|
|February 28, 2023||10,000||2,649.00||26,490,000|
|March 02, 2023||12,000||2,581.07||30,972,840|
|March 03, 2023||12,000||2,548.29||30,579,480|
|Accumulated under the program||78,000||204,581,960|
Details of each transaction are included as an appendix to this announcement.
Following these transactions, Genmab holds 621,416 shares as treasury shares, corresponding to 0.94% of the total share capital and voting rights.
The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 06 dated February 22, 2023.
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Marisol Peron, Senior Vice President, Global Communications and Corporate Affairs
T: +1 609 524 0065; E: firstname.lastname@example.org
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: email@example.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.
Company Announcement no. 13
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Kalvebod Brygge 43
1560 Copenhagen V
- 230306_CA13_Transactions in connection with share buyback program- Mar 03 2023
- Appendix_SBBP_specification for February 27 to March 3
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ny afdeling Balance C Akkumulerende i Investeringsforeningen PFA Invest31.3.2023 11:27:08 CEST | Press release
Investeringsforeningen PFA Invests bestyrelse har den 8. marts 2023 besluttet at oprette af en ny afdeling, Balance C Akkumulerende. Afdelingen blev godkendt af Finanstilsynet den 10. januar 2023. Vedlagt offentliggøres tegningsprospektet for afdelingen under Investeringsforeningen PFA Invest • Balance C Akkumulerende Andele i afdelingen udbydes til tegning fra den 11. april 2023 til den 24. april 2023, begge dage inklusive, og andele udbydes i tegningsperioden til tegningskurs 100,20. Tegning af min. 1 mio. kr. i afdelingen er garanteret af PFA Pension, forsikringsaktieselskab. Resultat af tegningen forventes offentliggjort den 25. april 2023. NASDAQ OMX Copenhagen A/S har godkendt at andelene optages til handel med forventet 1. handelsdag den 28. april 2023. Yderligere information kan findes på www.pfainvest.dk Med venlig hilsen PFA Asset Management A/S Attachment Tegningsprospekt PFA Invest - Balance C Akkumulerende
Indkaldelse til ordinær generalforsamling i EAC Invest A/S - Selskabsmeddelelse nr. 2/202331.3.2023 10:58:37 CEST | pressemeddelelse
København, 31. marts 2023 Den ordinære generalforsamling i EAC Invest A/S vil blive afholdt fredag den 28. april 2023 kl. 11:00 i Asia House, Indiakaj 16, 2100 København Ø. Vedhæftet dagsorden med bilag. Med venlig hilsen, for EAC Invest A/S Bestyrelsen For yderligere information Kresten M. Valdal, CEO,Telefon: +45 82334044, e-mail firstname.lastname@example.org Vedhæftede filer EAC Invest AS - AGM 2023 IndkaldelseEAC Invest AS - AGM 2023 - Bilag 1 - Bestyrelseskandidater2023.02 Indkaldelse til ordinær generalforsamling i EAC Invest AS
Decisions of Innofactor Plc’s Annual General Meeting and the organizing meeting of the Board of Directors31.3.2023 10:20:00 CEST | Press release
Innofactor Plc Stock Exchange Release March 31, 2023, at 11.20 Finnish time Adopting the accounts and the group's financial statement and granting the members of the Board of Directors and the Chief Executive Officer discharge from liability The Annual General Meeting (AGM) of Innofactor Plc held on March 31, 2023, resolved to adopt the accounts and the group's financial statement for the financial period that ended on December 31, 2022, and granted the members of the Board of Directors and the Chief Executive Officer discharge from liability for the financial period that ended on December 31, 2022. Deciding on the use of the profit shown on the balance sheet and the payment of dividend The AGM decided, in accordance with the proposal of the Board of Directors, that no dividend will be paid for the financial period of 2022. The AGM decided on a repayment of capital of EUR 0,06 per share to be paid. The repayment of capital shall be paid to shareholders who on the record date of the cap
AFARAK GROUP SE'S PUBLISHES FINANCIAL STATEMENTS 202231.3.2023 10:18:29 CEST | Press release
09:15 London, 11:15 Helsinki, 31 March 2023 - Afarak Group SE ("Afarak" or "the Company") (LSE: AFRK, OMX: AFAGR) Annual Financial Report AFARAK GROUP SE'S PUBLISHES FINANCIAL STATEMENTS 2022 Afarak Group announces that it has published today its Board of directors report, Financial Statement for the year 2022, the Auditor’s Report and the Corporate Governance Statement which is available from the Company's website www.afarak.com. Afarak publishes the Financial Statements in accordance with European Single Electronic Format (ESEF) reporting requirements with the XHTML format labelled with XBRL tags, which are available as zip file attached to this release. A copy of the Board of Directors report and the Financial Statements for the year 2022 has been submitted to the UK's National Storage Mechanism. Afarak will hold its 2023 Annual General Meeting in Helsinki on within the time stipulated in the Finnish Companies Act. Helsinki 31 March 2023 Guy Konsbruck CEO For additional information,
Agillic named a leader in The Cross-Channel Marketing Hubs Landscape, Q1 2023 report by Independent Research Firm31.3.2023 10:02:56 CEST | Press release
Press release, Copenhagen, 31 March 2023 Agillic’s Omnichannel Marketing Automation Platform has been named in Forrester’s ‘The Cross-Channel Marketing Hubs Landscape, Q1 2023’ report as a notable vendor among CCMH vendor options for B2C marketing. The Forrester report for Cross-Channel Marketing Hubs (CCMHs) allows B2C executives to understand the value they can expect from a CCMH vendor, learn how vendors differ, and select the right one based on size and market focus. In the report, Forrester defines CCMHs as ‘Enterprise marketing technology that supports customer data management, analytics, segmentation, and workflow tools for designing, executing, and measuring marketing engagement across digital and offline channels.’ The overview recognises that B2C marketers are shifting their CCMH investments from traditional campaigns to investing more in providing customers with personalized and meaningful interactions. Marketers can use Cross-Channel Marketing Hubs, according to Forrester,